PK/PD Integration — Effect Compartment & Indirect Response Models
PK/PD Integration — Effect Compartment & Indirect Response Models
In many drugs, there is a temporal dissociation (hysteresis) between the plasma concentration-time profile and the observed pharmacodynamic effect. This occurs because the drug must distribute to the biophase (effect site) before engaging receptors. The effect-compartment model (Sheiner, 1979) captures this lag with a first-order equilibration process characterised by $k_{eo}$ (or equivalently $t_{\frac{1}{2},k_{eo}}$). Indirect response models apply when the drug affects the production or degradation of a mediator.
1. Effect-Compartment (Biophase) Model
The effect site does not contribute significantly to drug mass balance (negligible volume). Drug distributes from plasma to effect site with rate constant $k_{eo}$ (equilibration rate):
$$\frac{dC_e}{dt} = k_{eo}(C_p(t) - C_e(t))$$
where $C_e$ is the effect-site concentration and $C_p(t)$ is the plasma concentration (known from PK model). Effect is driven by $C_e$, not $C_p$:
$$E(t) = E_0 + \frac{(E_{max}-E_0)C_e^n}{EC_{50}^n + C_e^n}$$
The hysteresis loop (E vs $C_p$ plot) collapses to a monotonic relationship when $E$ is plotted against $C_e$. The peak effect-site concentration lags behind peak plasma concentration by $t_{lag} \approx \ln(k_{eo}/k_e)/(k_{eo}-k_e)$ for a one-compartment PK model.
2. Effect-Site Equilibration Half-Life
$t_{\frac{1}{2},k_{eo}} = \ln 2 / k_{eo}$. Small $k_{eo}$ (long $t_{\frac{1}{2},k_{eo}}$) = slow equilibration, late and blunted effect; large $k_{eo}$ (short $t_{\frac{1}{2},k_{eo}}$) = rapid equilibration, effect closely tracks plasma. Clinical examples:
- Fentanyl: $t_{\frac{1}{2},k_{eo}} \approx 4$ min (fast CNS equilibration)
- Morphine: $t_{\frac{1}{2},k_{eo}} \approx 17$ min (slower, less lipophilic)
- Digoxin: $t_{\frac{1}{2},k_{eo}} \approx 200$ min (very slow myocardial equilibration)
3. Indirect Response Models (Mechanism-Based)
Many drugs modulate a physiological response mediated by a turnover process — they stimulate or inhibit the production ($k_{in}$) or degradation ($k_{out}$) of a response variable $R$:
$$\frac{dR}{dt} = k_{in} \cdot [1 \pm H(C)] - k_{out} \cdot R \cdot [1 \pm H(C)]$$
where $H(C) = E_{max}C/(EC_{50}+C)$ is the Hill function. At baseline: $R_0 = k_{in}/k_{out}$. Model I (inhibit $k_{in}$): warfarin on prothrombin. Model II (inhibit $k_{out}$): corticosteroids on cortisol. Model III (stimulate $k_{in}$): erythropoietin on RBC. Model IV (stimulate $k_{out}$): β-agonists on heart rate. The indirect models inherently produce a temporal delay without an effect compartment.
4. Tolerance & Clock Models
Tolerance (reduced response to the same concentration over time) arises from receptor downregulation, counter-regulatory feedback, or precursor depletion. The counter-regulatory mechanism model:
$$E_{obs}(t) = E_{direct}(C(t)) - E_{tolerance}(C(t), R(t))$$
where $R(t)$ is a tolerance state variable driven by $C(t)$. Opioid analgesic tolerance, nitrate tolerance in cardiovascular disease, and methylphenidate tolerance in ADHD are classical examples studied with this framework.
Worked Example — Effect-Compartment Simulation
After IV bolus: $C_p(t) = C_0 e^{-k_e t}$ with $k_e = 0.2$ h$^{-1}$, $C_0 = 10$ mg/L. Effect-site: $k_{eo} = 0.5$ h$^{-1}$, so $t_{\frac{1}{2},k_{eo}} = 1.39$ h. ODE solution: $C_e(t) = C_0 k_{eo}/(k_{eo}-k_e) \cdot (e^{-k_e t} - e^{-k_{eo}t}) = 10 \times 0.5/0.3 \cdot (e^{-0.2t} - e^{-0.5t}) = 16.67(e^{-0.2t}-e^{-0.5t})$. Peak $C_e$ at $t_{peak} = \ln(0.5/0.2)/(0.5-0.2) = 0.916/0.3 = 3.05$ h. $C_{e,peak} = 16.67(e^{-0.61}-e^{-1.525}) = 16.67(0.543-0.217) = 5.43$ mg/L. ✓
Practice Problems
Graphing Calculator
Statistics Calculator
| x |
|---|